What they were paid
BIOMARIN PHARMACEUTICAL Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $171,500 | $398,535 | $0 | $0 | $570,035 |
| FY2024 | $171,500 | $547,567 | — | $0 | $719,067 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOMARIN PHARMACEUTICAL INC DEF 14A filed April 21, 2026, accession 0001628280-26-026290, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025BIOMARIN PHARMACEUTICAL pays directors $400,000 in RSUs.
Committees
FY2025 · as the proxy prints themTransactions and Strategy (Chair)
The rest of the BIOMARIN PHARMACEUTICAL board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Alexander Hardy | Director | $0 |
| Athena Countouriotis, M.D | Independent Director | $493,660 |
| Barbara W. Bodem | Independent Director | $487,035 |
| Elizabeth McKee Anderson | Independent Director | $505,035 |
| Ian T. Clark | Independent Director | $451,230 |
| Mark J. Enyedy | Independent Director | $501,285 |
| Maykin Ho, Ph.D | Independent Director | $502,785 |
| Robert J. Hombach | Independent Director | $509,535 |
| Timothy P. Walbert | Independent Director | $492,785 |
| Willard Dere, M.D | Independent Director | $509,035 |
The full BIOMARIN PHARMACEUTICAL compensation record
free company briefThis page is one director within BIOMARIN PHARMACEUTICAL's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat